The positive results of the SPEARHEAD-1 trial which showed durable responses of afamitresgene autoleucel in unresectable or metastatic synovial sarcoma granted FDA accelerated approval
With a recent survey in collaboration with SIOPE and the recognition of LGBTQ as a specific patient population in the recommendations for a Global Curriculum in Medical Oncology, ESMO is at the forefront of a more inclusive oncology
The use of sunscreens is essential to protect the skin from UV exposure, but they may enter waterways damaging the ecosystem
In the MARIPOSA study, a significant improvement in progression-free survival was reported in a subgroup with poor prognostic factors
In the Cohort B of the TACTI-003 study, the combination therapy led to clinically meaningful response rates in patients with recurrent or metastatic disease
The aim is to harmonise results between different laboratories and facilitate clinical decision-making for physicians
In an ESMO-SIOPE survey, only 10% of respondents report they received adequate education in medical school about how to tailor cancer care to this population
Benefits reported for the combination of ipilimumab and nivolumab further expand alternative therapeutic options for patients with unresected advanced disease
Novel agents, a rethinking of accepted treatment concepts and new roles for older treatment modalities are now driving liver cancer management
Data from clinical trials show the value of liquid biopsy in treatment decision-making and prognostication
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.